scholarly journals Unique prognostic features of grade 3 endometrioid endometrial carcinoma: Findings from 101 consecutive cases at a Japanese tertiary cancer center

2021 ◽  
Vol 60 (2) ◽  
pp. 238-244
Author(s):  
Mayumi Kobayashi Kato ◽  
Hiroshi Yoshida ◽  
Takashi Uehara ◽  
Masaya Uno ◽  
Mitsuya Ishikawa ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Cancer Center ◽  
Prognostic Features ◽  
Endometrioid Endometrial Carcinoma ◽  
Grade 3 ◽  
Tertiary Cancer Center

Rationale for the utilization of biological targeted agents (bTAs) in the treatment of metastatic colorectal cancer (mCRC), single tertiary cancer center experience.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15589-e15589
Author(s):  
Ivan Barrera ◽  
Yahia A. Lakehal ◽  
Tomas Kavan ◽  
Petr Kavan
Keyword(s):  
Bowel Perforation ◽  
Primary Objective ◽  
Cancer Center ◽  
Gi Symptoms ◽  
Significant Difference ◽  
Common Grade ◽  
Jewish General Hospital ◽  
Grade 3 ◽  
Physician Patient ◽  
Tertiary Cancer Center

e15589 Background: Worldwide treatment for 1st line (1LTx) mCRC included doublet or triple chemotherapy with or without bTAs. In Quebec, the anti-EGFR therapy (panitumumab or cetuximab) was only recently approved in this setting for patients RAS WT, Bevacizumab (B) not eligible. In this study we evaluated the rational and outcomes using bTAs. Methods: Retrospective study assessing mCRC pts treated with or without bTAs at any time throughout the course of therapy at the Jewish General Hospital between 2010-2018. Pts were divided in 3 groups according to their 1LTx for analysis: Chemotherapy alone (1LChA), Chemotherapy plus B (1LChB), and anti-EGFR with or without chemotherapy (1LaEGFR). The primary objective was to assess the rational of bTAs prescription based in 1LTx selection. Secondary objectives included safety, PFS and OS. Results: Among a total of 463 pts with mCRC; 196 pts (42.3%) received 1LChA, 246 pts (53.2%) 1LChB, and 21 pts (4.5%) 1LaEGFR respectively. 1LChA group, 51% omitted bTAs for physician-patient preferences, 96 pts (49%) had contraindications for B, and 79 pts (40.3%) were potentially candidates for aEGFR, but did not receive it. 152/196 (77.5%) pts continued to 2LTx and 34.8% received bTAs. As for the 3LTx, 78/196 (40%) received a treatment, 48.7% received bTAs. The most common grade 3-4 adverse events (AEs) were hypertension and bowel perforation in B, gastrointestinal (GI) symptoms and skin reaction (SR) in aEGFR. 1LChB group, 31 pts (12.6%) presented AEs related to B. 191/246 pts (77.6%) continued to 2LTx with 48 pts (25%) receiving ChB despite progression in 1LTx on this bTA and 19 pts (10%) receiving aEGFR. The most common AEs reported in 2LTx were GI symptoms and neuropathy. In 3LTx, 54/91pts (59.3%) received aEGFR therapy and 8 pts (14.8%) had SR AEs. 46 pts (18.6%) continued to 4LTx, 13/46 pts (28.2%) received aEGFR. 1LaEGFR group, the most common AEs were SR and GI symptoms. 11/21 pts (52.3%) continued to 2LTx; 5 pts (45.4%) switching bTA class and receiving ChB. 81% pts started treatment between 2017-2018 and had at least two contraindication criteria for. The median PFS for the 1LChA and 1LChB groups were 10 and 11.5 months, respectively, and were not statistically significant (p=0.22). The OS with 1LChA and 1LChB was 33.26 vs. 27.80 months (p=0.27). The PFS and OS between 1LChA and 1LaEGFR were 10 vs 11 months (p= 0.27) and 33.26 vs. 35.07 months (p=0.13). Conclusions: The outcome and tolerability of bTAs in mCRC appear similar in our institution and randomised trials. We were not able to detect any significant difference among the three groups of comparison. The 1LaEGFR available data in this subset of patients are limited. Our data highlights the importance of optimal therapeutic sequencing to prolong OS. Dedicated studies are needed in order to determine the best bTAs therapeutic strategy in mCRC.

scholarly journals Analysis of recurrence and survival rates in grade 3 endometrioid endometrial carcinoma

2016 ◽  
Vol 12 (4) ◽  
pp. 2860-2867 ◽  
Author(s):  
Jieyu Wang ◽  
Nan Jia ◽  
Qing Li ◽  
Chao Wang ◽  
Xiang Tao ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Survival Rates ◽  
Endometrioid Endometrial Carcinoma ◽  
Grade 3

Incidence and severity of systemic allergic reactions (SAR) reported with chemotherapeutic drugs.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e18802-e18802
Author(s):  
Beulah Elsa Thomas ◽  
Anju Murugan ◽  
Hrishi Varayathu ◽  
Lalram Sangi ◽  
Sonia Rani ◽  
...  
Keyword(s):  
Overall Response Rate ◽  
Response Rate ◽  
Complete Response ◽  
Cancer Center ◽  
Grading System ◽  
Grade Classification ◽  
Grade 5 ◽  
Dose Number ◽  
Grade 3 ◽  
Tertiary Cancer Center

e18802 Background: SAR, a known adverse event of cancer therapy has variable severity. Despite the availability of many approved grading tools, there is still a lack of a globally applicable grading system. To address this, World Allergy Organization (WAO) created a uniform 5-grade classification system which was modified recently to be applicable for all SAR’s. This study aims to understand the incidence and severity of chemotherapy induced SAR and overall response rate (ORR) of rechallenged drugs in a tertiary cancer center. Methods: A retrospective single centered analysis of 103 patients with chemotherapy induced SAR was carried out. Patients were stratified based on age, gender, drugs given, dose number and severity of reaction. We used Modified WAO Grading System for assessing the severity. Descriptive statistics was applied to decipher the data. ORR is defined as the proportion of patients who have a partial or complete response to rechallenged drugs using RECIST Criteria for solid tumors and Lugano Classification for lymphoma. Results: Among 103 patients who reported SAR, 63.1% were female and 64.1% patients were less than 60 years of age. Among the 22 drugs, median dose number was high for Oxaliplatin (6) and Carboplatin (5). SAR was more observed with Paclitaxel (20.39%), Carboplatin (17.48%) and Rituximab (13.59%). However, carboplatin and rituximab had more incidence of grade 1 SAR(25.92% and 29.63% respectively). Grade 1 SAR (39.80%) were reported the highest followed by grade 3 (29.13%), grade 5 (13.59%), grade 2 (11.65%), and grade 4 (5.83%). Cetuximab precipitated the most grade 5 reactions (33.33%). Among patients exhibiting SAR with Paclitaxel, 42.86% were switched to alternatives, Nab-paclitaxel (28.57%) being preferred the most. Carboplatin was changed to cisplatin in 16.66% patients and Nanosomal docetaxel lipid suspension replaced docetaxel in 42.86% patients who reported SAR with carboplatin and docetaxel respectively. Rituximab was rechallenged the most (11.65%) off which one patient had reaction. ORR was observed to be 62.5% and 50% among rechallenged Paclitaxel and Rituximab respectively. The incidence of SAR is depicted in the below table. Conclusions: The study inferred that most SAR reactions occurred with Paclitaxel and Carboplatin. Oxaliplatin and Carboplatin presented with delayed SAR. Grade 1 and grade 3 reaction were relatively more. Cetuximab reported the most grade 5 reactions. ORR of rechallenged drugs should be monitored in further larger studies.[Table: see text]

Molecular Profile of Grade 3 Endometrioid Endometrial Carcinoma

2012 ◽  
Vol 36 (5) ◽  
pp. 753-761 ◽  
Author(s):  
Teresa Alvarez ◽  
Ezra Miller ◽  
Linda Duska ◽  
Esther Oliva
Keyword(s):  
Endometrial Carcinoma ◽  
Molecular Profile ◽  
Endometrioid Endometrial Carcinoma ◽  
Grade 3

scholarly journals Undifferentiated Endometrial Carcinoma: A Diagnosis Frequently Overlooked

2013 ◽  
Vol 137 (3) ◽  
pp. 438-442 ◽  
Author(s):  
Shaymaa Al-Loh ◽  
Maysa Al-Hussaini
Keyword(s):  
Endometrial Carcinoma ◽  
Cancer Center ◽  
Endometrioid Adenocarcinoma ◽  
Diagnostic Challenge ◽  
Gynecology And Obstetrics ◽  
Proper Definition ◽  
Grade 3 ◽  
Md Anderson ◽  
Endometrial Endometrioid Adenocarcinoma ◽  
Uncommon Neoplasm

Undifferentiated endometrial carcinoma (UEC) is a relatively uncommon neoplasm with only few studies published thus far. It has always been a diagnostic challenge because of the lack of proper definition cited in most of the standard textbooks. Recently however, a few studies have highlighted the clinicopathologic features of UEC. The distinctive morphology of UEC was noted by the group from MD Anderson Cancer Center, which enabled them to establish the defining criteria. It appears to be more aggressive than endometrial endometrioid adenocarcinoma, FIGO (International Federation of Gynecology and Obstetrics) grade 3, its main differential diagnosis. Proper recognition of this entity is important owing to its aggressive behavior.

scholarly journals Loss of ARID1A Expression as a Favorable Prognostic Factor in Early-Stage Grade 3 Endometrioid Endometrial Carcinoma Patients

2021 ◽  
Vol 27 ◽  
Author(s):  
Mayumi Kobayashi Kato ◽  
Hiroshi Yoshida ◽  
Yasuhito Tanase ◽  
Masaya Uno ◽  
Mitsuya Ishikawa ◽  
...  
Keyword(s):  
Adjuvant Therapy ◽  
Endometrial Carcinoma ◽  
Early Stage ◽  
Rank Test ◽  
Prognostic Impact ◽  
Protein Expressions ◽  
Impact On Survival ◽  
Endometrioid Endometrial Carcinoma ◽  
Grade 3 ◽  
Expression Status

Introduction: High-risk patients with grade 3 endometrioid endometrial carcinoma (G3EEC) who require adjuvant therapy have not been clearly identified. Therefore, the current study aimed to investigate the prognostic impact of ARID1A, p53, and mismatch repair (MMR) protein expressions, previously reported as prognosticators in some gynecological cancers, in patients with early-stage G3EEC.Methods: A total of 67 patients with pathologically confirmed early-stage G3EEC diagnosed between 1997 and 2020 were identified; none received adjuvant chemotherapy. The recurrence-free survival (RFS) and overall survival (OS) were estimated using the Kaplan-Meier method and compared with a log-rank test. The protein expressions of ARID1A, p53, and MMR were examined via immunohistochemistry, and the associations between these biomarkers and clinical outcomes were evaluated.Results: Recurrence was observed in 9 (13%) of the 67 patients with early stage G3EEC. The respective 5-years RFS and OS rates were 87.7% and 93.7%, and 68.6% and 85.7%, respectively for stages I and II. Multivariate analysis showed significantly longer RFS among patients with ARID1A loss (hazard ratio = 8.7; 95% CI, 1.09–69.6, p = 0.04). No significant differences were observed in RFS and OS of patients according to p53 and MMR expression status.Conclusion: ARID1A expression status was a prognosticator for patients with early stage G3EEC without adjuvant therapy, whereas p53 and MMR expression status showed no impact on survival outcomes. ARID1A may become a useful biomarker for stratification of adjuvant treatment for early stage G3EEC patients.

Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer—A clinical and pathological evaluation

2012 ◽  
Vol 124 (1) ◽  
pp. 15-20 ◽  
Author(s):  
Martin A. Voss ◽  
Raji Ganesan ◽  
Linmarie Ludeman ◽  
Keith McCarthy ◽  
Robert Gornall ◽  
...  
Keyword(s):  
Endometrial Carcinoma ◽  
Pathological Evaluation ◽  
Endometrioid Endometrial Carcinoma ◽  
Grade 3
Sign in / Sign up

Export Citation Format

Share Document